Tunitas Therapeutics Inc., of San Francisco, was awarded a Small Business Innovation Research Phase II grant from the National Institute of Allergy and Infectious Disease
The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is being conducted at the NIAID Phase I Clinical Trials Unit at Case Western Reserve University in Cleveland
Sorrento Therapeutics Inc. (STI), of San Diego, said the National Institute of Allergy and Infectious Diseases renewed the second year of a two-year Phase I fast-track advanced technology small business technology transfer research (STTR) grant to support the development of human antibody therapeutics to combat Staphylococcus aureus infections, including methicillin-resistant S
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it will receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases to advance the development of its next-generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation...Advancements from the project are expected to enable rapid and efficient delivery of Inovio's SynCon vaccines for universal flu, HIV and other infectious diseases
VaxInnate Corp., of Cranbury, N.J., said it received a grant from the National Institute of Allergy and Infectious Diseases to fund the development of a recombinant vaccine for the prevention of dengue
NeoStem Inc., of New York, said it was awarded the second year of a two-year grant totaling $595,252 from the National Institute of Allergy and Infectious Diseases for the development of human, autologous, pluripotent very small embryonic-like (VSEL) stem cells as a countermeasure to radiation threats
Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus, when other alternatives are not suitable...In other news, Elan said its Tysabri (natalizumab) restructuring transaction is
BioWorld International | Wednesday, March 13, 2013
Cubist Pharmaceuticals Inc., of Lexington, Mass., said the FDA designated its late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of hospital-acquired pneumonia, ventilator-associated bacterial pneumonia and complicated urinary tract infections
Furiex Pharmaceuticals Inc., Morrisville, N.C., said avarofloxacin, a Phase III-ready product, received Qualified Infectious Disease Product and fast-track designations from the FDA
Altravax Inc., of Fargo, N.D., said it received two Advanced Technology Small Business Innovation Research grants from the National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. In recent months, the firm has received more than $4.5 million in nondilutive funding
Under the agreement, Pepscan will use its CLIPS platform and other protein mimicry technologies to help discover new antibodies...to purchase up to 1 million shares, or about 1.06 percent of the company's outstanding stock, at a price of $161.25 per share, marking a 4.46 percent discount to the Dec. 27 closing price
The study, conducted under the National Institute of Allergy and Infectious Diseases' Preclinical Services Program, was designed to test multiple DepoVax-formulated vaccines, specifically examining immunogenicity and safety after either one or two doses...Paratek Pharmaceuticals Inc., of Boston, said the FDA designated the firm's lead antibiotic candidate, omadacycline (formerly PTK 0796) as a Qualified Infectious Disease Product (QIDP) for both intravenous and oral formulations to treat acute
Sarepta Therapeutics Inc., of Cambridge, Mass., signed a clinical trial agreement with the National Institute of Allergy and Infectious Diseases to carry out a Phase I study of its influenza candidate, AVI-7100...It is the second of three infectious disease indications the company intends to pursue as part of its August 2012 collaboration with Intrexon
The technology has the potential to enhance antibody therapeutics for a broad range of applications in cancer and infectious diseases, according to the company
Cubist Pharmaceuticals Inc., of Lexington, Mass., said that the FDA has designated two of its Phase III antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP
Tunitas Therapeutics Inc., of San Francisco, was awarded a Small Business Innovation Research Phase II grant from the National Institute of Allergy and Infectious Disease